Literature DB >> 10354049

Primary cutaneous CD30 (Ki-1)-positive anaplastic large cell lymphoma associated with renal cell carcinoma.

S A Shah, A D Ormerod, A Husain, P Kohle, D Culligan.   

Abstract

Entities:  

Mesh：

Year:  1999        PMID： 10354049     DOI： 10.1046/j.1365-2133.1999.02843.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  4 in total

1.  Concomitant renal cell carcinoma and lymphoid malignancies: a case series of five patients and review of the literature.

Authors:  Songul Serefhanoglu; Yahya Buyukasik; Hakan Goker; Safak Cavus Akin; Serkan Akin; Nilgun Sayinalp; Ibrahim Celalettin Haznedaroglu; Osman Ilhami Ozcebe
Journal:  Med Oncol       Date:  2009-02-11       Impact factor: 3.064

Review 2.  EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.

Authors:  Werner Kempf; Katrin Pfaltz; Maarten H Vermeer; Antonio Cozzio; Pablo L Ortiz-Romero; Martine Bagot; Elise Olsen; Youn H Kim; Reinhard Dummer; Nicola Pimpinelli; Sean Whittaker; Emmilia Hodak; Lorenzo Cerroni; Emilio Berti; Steve Horwitz; H Miles Prince; Joan Guitart; Teresa Estrach; José A Sanches; Madeleine Duvic; Annamari Ranki; Brigitte Dreno; Sonja Ostheeren-Michaelis; Robert Knobler; Gary Wood; Rein Willemze
Journal:  Blood       Date:  2011-08-12       Impact factor: 22.113

3.  A coincidence of renal cell carcinoma and hematological malignancies.

Authors:  Gokhan Sargın; Irfan Yavasoglu; Firuzan Kacar Doger; Gurhan Kadikoylu; Zahit Bolaman
Journal:  Med Oncol       Date:  2012-07-29       Impact factor: 3.064

4.  Occurrence of renal cell carcinoma and hematologic malignancies (predominantly lymphoid) in individuals and in families.

Authors:  Janice P Dutcher; Peter H Wiernik; Leticia Varella; Rangaswamy Chintapatla
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.